Andy Harrison joins Section 32 from executive leadership roles at Alphabet, including Verily Life Sciences (previously Google Life Sciences) and X (previously GoogleX). Andy brings deep market knowledge and commercial experience to Section 32. As the Head of Business and Corporate Development at Verily, Andy’s team executed global go-to-market campaigns for a wide range of next-generation technologies, building creative and pioneering partnerships, collaborations and joint ventures on a global basis. Andy co-founded and ran Verily’s venture capital team, a strongly performing program that made early stage investments in leading start-ups developing advanced technologies and digital health solutions. At Google, Andy also advised a variety of platforms across automation, quantum, cybersecurity, machine learning, artificial intelligence and other technology disciplines.
Susan Hager is a life sciences brand builder. Most recently, Sue held senior leadership roles at two stand-out life sciences companies with close ties to Section 32, EQRx and Foundation Medicine. At EQRx, Sue led the creation of the company’s award-winning brand and contributed to its financing efforts securing approximately $750M since its inception in 2019. Previously, Sue helped build Foundation Medicine into one of the leading global brands in genomic cancer testing. During her career, she has led product launches for more than two dozen diagnostic, therapeutic and digital health products worldwide, in addition to supporting growth-oriented corporate fundraising objectives.
This news builds upon a strong year for Section 32. We closed Fund 3 (bringing total assets under management to over $1B) and more than doubled our team. Sue and Andy round out our exceptional team united in a mission to push the boundaries of what’s possible in technology and healthcare. Stay tuned for our next chapter and beyond.
About Section 32:
Section 32 is a venture capital fund investing at the frontiers of technology and healthcare. Founded by Bill Maris, the team has vast experience building iconic companies. The firm’s goal is to improve the human condition by accelerating the discovery, development and distribution of important technologies and life saving medicines. Section 32 invests across the entirety of technology and healthcare. This includes software, cybersecurity, advanced communications and computation, space, climate change related technologies, machine learning, artificial intelligence, biotechnology, therapeutics, advanced diagnostics, precision medicine, genomics and more.